Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker’s shares seemed to get a lift from …
: https://www.fool.com/investing/2017/07/13/is-juno-therapeutics-stock-still-a-strong-buy.aspx